Nestle launches Vital Pursuit foods, suitable for those using GLP-1 drugs like Wegovy or Ozempic; designed to support balanced diets and portion-aligned for such consumers.
GLP-1 medications like semaglutides are increasingly popular for weight management, causing concern for food retailers as these drugs suppress appetite, potentially affecting profits.
Approximately 9 million Americans used GLP-1 meds in 2023, with a projected increase to 30 million by 2030, boosting the semaglutide market to over $100 billion.
Nestle's move to introduce high-fiber, protein-packed foods for weight management aligns with the trend of growing GLP-1 medication usage for various health benefits.
[
add
]
[
|
|
...
]